Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2017
At a glance
- Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary) ; Hepatitis A-hepatitis B vaccine; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Malaria
- Focus Adverse reactions
- 02 Nov 2017 Status changed from active, no longer recruiting to completed.
- 04 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 23 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017.